CING
Cingulate Inc (CING)
Healthcare • NASDAQ • $5.27+0.76%
- Symbol
- CING
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $5.27
- Daily Change
- +0.76%
- Market Cap
- $64.56M
- Trailing P/E
- N/A
- Forward P/E
- -3.62
- 52W High
- $11.89
- 52W Low
- $3.20
- Analyst Target
- $28.70
- Dividend Yield
- N/A
- Beta
- -0.81
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Company websiteResearch CING on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.